S. Mulangu

发表

Serologic Evidence of Ebolavirus Infection in a Population With No History of Outbreaks in the Democratic Republic of the Congo

J. Shiloach, N. Sullivan, P. Mulembakani, 2018, The Journal of infectious diseases.

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.

Michael Proschan, Lori E Dodd, Jerome Pierson, 2019, The New England journal of medicine.

Generic Detection of Coronaviruses and Differentiation at the Prototype Strain Level by Reverse Transcription-PCR and Nonfluorescent Low-Density Microarray

L. Poon, J. Drexler, C. Drosten, 2007, Journal of Clinical Microbiology.

Marburg hemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of illness, and treatment.

M. V. Van Kerkhove, P. Rollin, D. Bausch, 2007, The Journal of infectious diseases.

A New Approach for Monitoring Ebolavirus in Wild Great Apes

N. Sullivan, B. Hahn, B. Keele, 2014, PLoS neglected tropical diseases.

Structural and molecular basis for Ebola virus neutralization by protective human antibodies

U. Baxa, N. Sullivan, A. Lanzavecchia, 2016, Science.

Safety and Immunogenicity of DNAVaccines Encoding Ebolavirus and Marburgvirus Wild- Type Glycoproteins in a Phase I Clinical Trial

J. Mascola, R. Koup, N. Sullivan, 2015 .

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial

J. Mascola, R. Koup, N. Sullivan, 2014, The Journal of infectious diseases.

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

J. Mascola, R. Koup, C. Andrews, 2010, Vaccine.

Marburg hemorrhagic fever associated with multiple genetic lineages of virus.

Alan Kemp, Herwig Leirs, P. Formenty, 2006, The New England journal of medicine.

Use of protective gear and the occurrence of occupational Marburg hemorrhagic fever in health workers from Watsa health zone, Democratic Republic of the Congo.

P. Lefèvre, P. van der Stuyft, M. Borchert, 2007, The Journal of infectious diseases.

Serosurvey on Household Contacts of Marburg Hemorrhagic Fever Patients

P. van der Stuyft, M. Borchert, R. Swanepoel, 2006, Emerging infectious diseases.

Pygmy Populations Seronegative for Marburg Virus

P. van der Stuyft, M. Borchert, R. Swanepoel, 2005, Emerging infectious diseases.

Lessons from the outbreak of Marburg virus.

P. van der Stuyft, M. Borchert, S. Mulangu, 2005, The New England journal of medicine.

A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats

M. Halloran, T. Fleming, C. Donnelly, 2022, Clinical trials.

Development of the PREDS score to predict in-hospital mortality of patients with Ebola virus disease under advanced supportive care: Results from the EVISTA cohort in the Democratic Republic of the Congo

K. Ezzedine, J. Muyembe, D. Malvy, 2022, EClinicalMedicine.

Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge

Joshua C. Johnson, R. Koup, N. Sullivan, 2011, Journal of Virology.

Development of Ebola virus disease prediction scores: Screening tools for Ebola suspects at the triage-point during an outbreak

L. Lynen, S. Ahuka-Mundeke, D. Tshala-Katumbay, 2022, PloS one.

High prevalence of IgG antibodies to Ebola virus in the Efé pygmy population in the Watsa region, Democratic Republic of the Congo

P. van der Stuyft, M. Borchert, J. Pawęska, 2016, BMC Infectious Diseases.

Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species

Joshua C. Johnson, R. Koup, N. Sullivan, 2010, PLoS pathogens.

Ebola virus outbreaks in Africa: past and present.

J. Pawęska, A. Kemp, J. Masumu, 2012, The Onderstepoort journal of veterinary research.

Ebolavirus vaccines for humans and apes.

N. Sullivan, H. Fausther-Bovendo, S. Mulangu, 2012, Current opinion in virology.

Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection

S. Mulangu, Olivier Tshiani Mbaya, Philippe Mukumbayi, 2021, Frontiers in Immunology.

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

J. Mascola, N. Sullivan, F. Sallusto, 2016, Science.

The Prophylactic and Therapeutic Efficacy of the Broadly Active Antiviral Ribonucleoside N4-Hydroxycytidine (EIDD-1931) in a Mouse Model of Lethal Ebola Virus Infection

A. Kolykhalov, Gregory R. Bluemling, M. Natchus, 2022, bioRxiv.

Virus kinetics and biochemical derangements among children with Ebolavirus disease

P. Formenty, S. Ahuka-Mundeke, M. Hawkes, 2022, EClinicalMedicine.

Antibody Use during an Outbreak of Ebola Virus Disease in the Democratic Republic of Congo, 2020.

S. Mulangu, O. T. Mbaya, P. Mbala-Kingebeni, 2022, The New England journal of medicine.

843. The PALM Consortium: A Multicenter, Multioutbreak Randomized Controlled Trial of Ebola Virus Disease Therapeutics

S. Mulangu, 2019, Open Forum Infectious Diseases.

Shifting the Paradigm - Applying Universal Standards of Care to Ebola Virus Disease.

D. Bausch, J. Muyembe, D. Wohl, 2019, The New England journal of medicine.

Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks.

Philip R Krause, Thomas Jaki, M Elizabeth Halloran, 2020, The New England journal of medicine.

Serosurvey on Household Contacts of Marburg Hemorrhagic Fever Patients

P. van der Stuyft, M. Borchert, R. Swanepoel, 2006, Emerging infectious diseases.

Rhabdomyolysis, Acute Kidney Injury, and Mortality in Ebola Virus Disease: Retrospective Analysis of Cases From the Eastern Democratic Republic of the Congo, 2019

Z. Mumtaz, S. Mulangu, D. Mukadi-Bamuleka, 2024, The Journal of infectious diseases.